Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
GPRO Hot Sheet
Rating Summary:4 Buy, 15 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Natixis Bleichroeder initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy. Price target $49.
To see more analyst ratings on GPRO Click Here.
Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally.
To see more analyst ratings on GPRO Click Here.
Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- PCA3 Test Featured at American Urological Association Meeting
- Barrington Research Starts Continental Resources (CLR) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Natixis BleichroederSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
